R&D News | pharmaphorum

News

Chris Cargill, Sosei Heptares chief executive

Sosei snaps up Idorsia’s Japan, Korea units in $466m deal

Japan’s Sosei Group has completed a transition to a commercial-stage pharmaceutical company after buying rights to an already-marketed drug and a pipeline of experimental

News

Study backs earlier use of Keytruda in cervical cancer

A phase 3 trial of Merck & Co’s checkpoint inhibitor Keytruda could support the expansion of its use in cervical cancer to include newly-diagnosed patients with less s

News

London’s life sciences skyscraper gets planning consent

Plans for a major life sciences development at Canary Wharf in London, UK, have been approved by the local authorities, allowing the project to go ahead.

News

Hearing aids could cut cognitive decline in some patients

With so much attention focused on the use of pricey amyloid-busting therapies for A

News

Pieris wields axe after losing AZ as partner for elarekibep

AstraZeneca has terminated a partnership with Pieris Pharmaceuticals on respiratory drug candidate elarekibep, forcing the latter to slash staff and look into its “strateg

News

Paul Biondi of Flagship's Pioneering Medicines

Pfizer inks $7bn strategic level R&D deal with Flagship

Pfizer has just made venture capital firm Flagship Pioneering a key component of its R&D engine, signing a deal worth up to $7 billion that will allow it to harvest ne

Sosei snaps up Idorsia’s Japan, Korea units in $466m deal

Study backs earlier use of Keytruda in cervical cancer

London’s life sciences skyscraper gets planning consent

Hearing aids could cut cognitive decline in some patients

Pieris wields axe after losing AZ as partner for elarekibep

Pfizer inks $7bn strategic level R&D deal with Flagship

Moderna cries foul as FDA blocks filing of mRNA flu shot

How to meet your physicians where they are online

News

Editor's Picks